APR 15, 2017 07:13 AM PDT

Biomarker Predicts Aggressiveness of a Breast Cancer

WRITTEN BY: Xuan Pham

Though breast cancer is one of the more publicized and well-studied cancer types, treatment for this disease remains imperfect. Many women are overdiagnosed while some don’t receive sufficient treatment to prevent metastasis. But scientists say the guessing game over a breast cancer’s aggressiveness could soon be over. They’ve identified a molecular biomarker that can distinguish between likely non-invasive to likely aggressive breast cancer – critical information that could alter treatment and subsequent outcomes for thousands of women.

The same breast cancer diagnosis does not guarantee the same outcome. In some cases, the breast cancer is so slow-growing that it doesn’t invade and may even be considered benign. By contrast, some breast cancers are so aggressively invasive that doctors have to continually play catch up with the cancer. It’s clear that a cancer as complex as breast cancer can’t have a one-size-fits-all approach. But how can doctors tell from the onset?

By intensely pouring through the expression profiles of about 350 genes associated with breast cancer, researchers from the Whitehead Institute say they’ve found a culprit for cancer aggressiveness. "Early-stage cancers are not all the same. Some are destined to go rogue and should be treated from the outset with this understanding in mind," said Piyush Gupta, the senior study author.

The gene is known as SMARCE1, and is involved in transcriptional activation and repression of other genes. Gupta and colleagues found that SMARCE1 was abundant in early-stage cancers that are more likely to have aggressive outcomes.

"It's clear that SMARCE1 is affecting all of the key players in invasion and metastasis," said Ethan Sokol, the study’s lead author. "It's amazing when you look at the list of the things it's regulating."

"We looked at every step of the metastatic cascade, and the tumor growth at the primary site, as well as the growth at the distant metastases, are not affected by this gene," said Yu-Xiong Feng, the study’s co-author. "Only the invasion is affected by SMARCE1." In other words, SMARCE1 is involved in tumor metastasis.

When SMARCE1 levels were analyzed in tissue samples from hundreds of early stage breast cancer patients, the team found a clear trend: those with higher SMARCE1 expression were more likely to have cancer metastasis. SMARCE1 seemed to be required for breast cancer cells’ escape to secondary sites.

The results provide a clear biomarker for sorting out patients who may require the full arsenal of chemotherapy and radiation, versus those patients in whom careful monitoring may be sufficient. Of course further validation on the SMARCE1 biomarker is needed, but already the study has big implications on how treatment can be personalized to every breast cancer patient’s unique disease.

Additional source: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 02, 2018
Cell & Molecular Biology
SEP 02, 2018
Cancer Cell Lines can Evolve in the Lab
New research shows that scientists have to take steps to verify the identity of the cell lines they grow....
OCT 04, 2018
Genetics & Genomics
OCT 04, 2018
Similar Processes Drive the Development of Lung and Prostate Cancers
Small cell cancers often have poor prognoses....
NOV 05, 2018
Cell & Molecular Biology
NOV 05, 2018
Using Imaging to Understand Cancer Growth
Most types of cells in our body go through a critical renewal process in which cells divide into two new ones. But it can get out of control as well....
DEC 03, 2018
Cancer
DEC 03, 2018
Using bubbly nano-particles for chemotherapy delivery
We have all heard about the harsh side effects of chemotherapy that could be so difficult leading to stopping treatment. The reason behind those side effects is that chemotherapy drugs do tar...
DEC 06, 2018
Drug Discovery
DEC 06, 2018
Repurposing Cancer Drugs For HPV Treatment
Drug repurposing is transforming the health care world. The idea that old, previously-- FDA approved drugs could be altered and to be used again for the tr...
DEC 16, 2018
Health & Medicine
DEC 16, 2018
Important Biomedical Research At Risk Of Being Defunded
In September the Department of Health and Human Services (D.H.H.S.) released a statement citing “serious regulatory, moral and ethical considerations...
Loading Comments...